Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072271 | 1.00 | GRIN2B (0.50) | GRIN2BKDM4ESPHK1OPRM1OPRD1 | |
| SCHEMBL5690258 | 0.95 | GRIN2B (0.53) | GRIN2BKDM4ESPHK1OPRM1OPRD1 | |
| SCHEMBL5690254 | 0.95 | GRIN2B (0.53) | GRIN2BKDM4ESPHK1OPRM1OPRD1 | |
| SCHEMBL6841392 | 0.85 | KDM4E (0.56) | GRIN2BKDM4ESPHK1OPRM1OPRD1 | |
| SCHEMBL6836225 | 0.85 | KDM4E (0.56) | GRIN2BKDM4ESPHK1OPRM1OPRD1 | |
| SCHEMBL6482674 | 0.84 | KMT2A (0.47) | SPHK1OPRM1OPRD1OPRK1 | |
| SCHEMBL5689734 | 0.84 | OPRM1 (0.44) | GRIN2BSPHK1OPRM1OPRD1OPRK1 | |
| SCHEMBL4691368 | 0.81 | GRIN2B (0.47) | GRIN2BKDM4EOPRM1OPRD1OPRK1 | |
| SCHEMBL5690181 | 0.81 | BCHE (0.50) | GRIN2BSPHK1 | |
| SCHEMBL5690183 | 0.81 | BCHE (0.50) | GRIN2BSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225164-A1 | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225164-A1 | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists | GRIN1, GRIN3A, GRIN2A | GRIN2B 4/4885KDM4E 2266/4885SPHK1 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.